Drug approval in Japan questioned [7]

Lancet

Volumn 352, Issue 9126, 1998, Pages 491-

  Hayashi, K ^a   Hashimoto, K ^a   Yanagi, M ^a   Umeda, T ^a   Hama, R ^a  

^a TAKATSUKI RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIFEMELANE; IDEBENONE; INDELOXAZINE; PROPENTOFYLLINE;

BRAIN METABOLISM; DOCTOR PATIENT RELATION; DRUG APPROVAL; HEALTH CARE POLICY; HUMAN; JAPAN; LETTER; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STROKE;

EID: 17644444061     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)79232-1     Document Type: Letter

References (5)

1. Significance to designate hopatenate calcium as dangerous drug Informed Prescrib 4 1989 17 21
2. M Yanagi K Hashimoto T Umeda Problems on the clinical evaluation methods with Zenpan Kaizendo Jap J Clin Pharmacol Therapeutics 26 1995 115 116 (in Japanese).
3. K Hashimoto N Irie E Takamoto Problems on the clinical evaluation methods of “cerebral-metabolism and circulation enhancers” Jap J Clin Pharmacol Therapeutics 27 1996 303 304 (in Japanese).
4. K Hayashi R Hama Evaluation of oral anti-allergic drugs in Japan Lancet 347 1996 477
5. D Berger I Fukunishi Psychiatric drug development in Japan Science 273 1996 318